Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
Articles, Neurobiology of Disease

Glucocorticoids Increase Amyloid-β and Tau Pathology in a Mouse Model of Alzheimer’s Disease

Kim N. Green, Lauren M. Billings, Benno Roozendaal, James L. McGaugh and Frank M. LaFerla
Journal of Neuroscience 30 August 2006, 26 (35) 9047-9056; DOI: https://doi.org/10.1523/JNEUROSCI.2797-06.2006
Kim N. Green
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren M. Billings
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benno Roozendaal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James L. McGaugh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank M. LaFerla
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Glucocorticoids enhance Aβ production in a time- and concentration-dependent manner. N2A cells were incubated with dexamethasone (100 nm to 10 μm; n = 3 per condition) (a) or corticosterone (100 nm to 10 μm; n = 3 per condition) (b) for 24–72 h, and Aβ levels were measured from cell media by sandwich ELISA. Aβ42 levels were expressed as a percentage of control Aβ40, shown in the thatched area. *p < 0.05, significance versus controls for either Aβ40 or Aβ42. Control Aβ40 levels average out at ∼1 pg of Aβ40 microgram of protein for a 24 h period into 1 ml of media. c, N2A cells were incubated for 72 h with or without mifepristone (Mif; 10 μm; n = 3) or spironolactone (Spiro; 100 nm; n = 3) and in the presence or absence of 1 μm dexamethasone (Dex; n = 3 per condition), and media Aβ levels were measured. *p < 0.05, significance versus controls for either Aβ40 or Aβ42. d, Treatment of N2A cells with dexamethasone (Dex; 1 μm, 48 h; n = 3) or corticosterone (Cort; 5 μm, 48 h; n = 3) or control (Con; 48 h; n = 3) increases steady-state levels of full-length APP and selectively increases in C99 as shown by Western blot. e, Quantification of d with protein levels normalized to β-actin levels as a loading control. *p < 0.05, significance versus controls. f, mRNA levels of mouse APP and BACE are increased after 72 h treatment with 10 μm dexamethasone, as measured by real-time PCR. *p < 0.05, significance versus controls. g, Pulse chase analyses of 35S-labeled APP after treatment of N2A cells with 10 μm dexamethasone for 72 h (D; n = 3) or control (C; n = 3). Cells were pulsed with 35S, after starvation, for 1 h and chased at the 0, 1, 4, and 8 h time points.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Dexamethasone treatment increases Aβ, C99, and BACE in the 3×Tg-AD mouse model. Four-month-old male 3×Tg-AD mice were treated daily for 7 d with 1 mg/kg (n = 5) or 5 mg/kg (n = 8) dexamethasone (Dex) or PBS vehicle (n = 8). a, Detergent-soluble Aβ levels were measured in whole-brain homogenates. Mice treated with 5 mg/kg dexamethasone (7 d; black bars) had significantly higher levels of Aβ40 and Aβ42 than vehicle-treated (PBS, 7 d; white bars) mice, whereas mice treated with 1 mg/kg dexamethasone (7 d; gray bars) had elevated Aβ42 compared with PBS controls. *p < 0.05, significance versus PBS controls for either Aβ40 or Aβ42; #p < 0.05, significance versus 1 mg/kg dexamethasone treatment. b, Detergent-insoluble Aβ40 and Aβ42 levels were significantly increased between 5 mg/kg dexamethasone treated and vehicle treated. c, e, DAB staining with 6E10 shows Aβ-like immunoreactivity in 40 μm sections from vehicle-treated mice. Hippocampus and amygdala regions are shown at 10× magnification. Inset demonstrates 40× confocal images with Aβ-like immunoreactivity shown in green and nuclear stain TOTO red shown in red. d, f, Same staining but in dexamethasone-treated animals. Aβ-like immunoreactivity was elevated in cell bodies of the hippocampus, as also shown by confocal imaging. g, Quantification of 6E10 DAB immunoreactivity in hippocampal and amygdala regions from PBS-treated and 5 mg/kg dexamethasone-treated groups. h, DAB staining with anti-CD45 shows that no activated microglia could be detected in the hippocampus of either PBS- or dexamethasone-treated animals. i, Western blot analyses of protein extracts from whole-brain homogenates of dexamethasone- and vehicle-treated 3×Tg-AD mice, shown as alternating lanes: P, PBS vehicle; D, 5 mg/kg dexamethasone treated. j, Quantification of protein blots from i shown normalized to β-actin levels as a loading control. Steady-state levels of APP are increased in the dexamethasone-treated group (6E10), whereas a 60 kDa band is similarly decreased, suggesting alternative processing. cAPP levels are unaltered, whereas C99 levels are increased but C83 levels remain unchanged. Furthermore, steady-state levels of BACE protein are increased concomitant to C99 levels. *p < 0.05, significance versus PBS controls.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Dexamethasone (Dex) treatment in 3×Tg-AD mice increases tau accumulation. Four-month-old male 3×Tg-AD mice were treated daily for 7 d with 5 mg/kg dexamethasone (n = 8) or PBS vehicle (n = 8). a, c, Immunostaining with anti-tau antibody HT7 shows little immunoreactivity in 40 μm sections from PBS vehicle-treated mice. Hippocampus and amygdala regions are shown at 10× magnification. Inset demonstrates 40× confocal images with HT7 immunoreactivity shown in green and nuclear stain TOTO red shown in red. b, d, Same staining but in 5 mg/kg dexamethasone-treated animals. HT7 immunoreactivity was elevated in cell bodies of the hippocampus and throughout the neuronal processes, as also shown by confocal imaging. e, Quantification of HT7 DAB immunoreactivity in hippocampal and amygdala regions from PBS-treated and 5 mg/kg dexamethasone-treated groups. f, DAB staining of no primary controls shown from hippocampus of PBS-treated and 5 mg/kg dexamethasone-treated animals, 10×. g, Western blot analyses of protein extracts from whole-brain homogenates of dexamethasone- and vehicle-treated 3×Tg-AD mice, shown as alternating lanes (P, PBS vehicle; D, 5 mg/kg dexamethasone treated) showing increases in total human tau steady-state levels (HT7) but no differences in phospho-tau (AT8 and AT180). h, Quantification of protein blots from g shown normalized to β-actin levels as a loading control. i, 2×Tg mice (PS1M146VKI and tauP301L, lacking the human APP transgene) treated daily with dexamethasone (5 mg/kg, 7 d; n = 3) or vehicle (PBS, 7 d; n = 3). Staining with HT7 shows no immunoreactivity in 40 μm sections from vehicle-treated or 5 mg/kg dexamethasone-treated mice. Hippocampus region is shown at 10× magnification. DAB HT7 immunoreactivity was unchanged from vehicle.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Dexamethasone (Dex) treatment increases insoluble Aβ in 13-month-old 3×Tg-AD mice. Thirteen-month-old male 3×Tg-AD mice were treated daily for 7 d with 5 mg/kg dexamethasone (n = 4) or PBS vehicle (n = 4). a, Detergent-soluble Aβ levels were measured in whole-brain homogenates. Mice treated with dexamethasone (5 mg/kg, 7 d; black bars) had significantly higher levels of Aβ40 and Aβ42 than vehicle treated (PBS, 7 d; white bars). b, Detergent-insoluble Aβ levels were significantly different between dexamethasone treated and vehicle treated. *p < 0.05, significance versus PBS controls for either Aβ40 or Aβ42. c, Western blot analyses of protein extracts from whole-brain homogenates of 13-month-old dexamethasone- and vehicle-treated 3×Tg-AD mice, shown as alternating lanes (P, PBS vehicle; D, 5 mg/kg dexamethasone treated) showing no differences in total or phosphorylated-tau (PHF). d, Quantification of protein blots from c shown normalized to β-actin levels as a loading control. e, Immunostaining with anti-tau antibody HT7 shows little immunoreactivity in 40 μm sections from 13-month-old PBS vehicle-treated 3×Tg-AD mice. Cortical region is shown at 10× magnification. f, Same staining but in dexamethasone-treated animals. DAB HT7 immunoreactivity was notably elevated in cell bodies and processes in the cortex, which was absent in PBS-treated vehicles.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Plasma corticosterone levels from 3×Tg-AD mice compared with NonTg over time. a, Plasma obtained from 3×Tg-AD and NonTg mice was taken and corticosterone levels were measured at 2, 4, 6, 9, 12, 15, and 18 months of age. No significant changes are seen at 2, 4, and 6 months. At 9 months and older, 3×Tg-AD mice have significantly higher plasma corticosterone levels than NonTg mice. *p < 0.05, significance versus NonTg animals at that time point. b, Western blot analyses of protein extracts from hippocampal homogenates of 4- and 15-month-old NonTg and 3×Tg-AD mice (n = 4 per group), shown as alternating lanes (C, NonTg control; 3, 3×Tg-AD), showing no differences in glucocorticoid receptor (GR) steady-state levels. c, Quantification of protein blots from b shown normalized to β-actin levels as a loading control.

Back to top

In this issue

The Journal of Neuroscience: 26 (35)
Journal of Neuroscience
Vol. 26, Issue 35
30 Aug 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Glucocorticoids Increase Amyloid-β and Tau Pathology in a Mouse Model of Alzheimer’s Disease
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Glucocorticoids Increase Amyloid-β and Tau Pathology in a Mouse Model of Alzheimer’s Disease
Kim N. Green, Lauren M. Billings, Benno Roozendaal, James L. McGaugh, Frank M. LaFerla
Journal of Neuroscience 30 August 2006, 26 (35) 9047-9056; DOI: 10.1523/JNEUROSCI.2797-06.2006

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Glucocorticoids Increase Amyloid-β and Tau Pathology in a Mouse Model of Alzheimer’s Disease
Kim N. Green, Lauren M. Billings, Benno Roozendaal, James L. McGaugh, Frank M. LaFerla
Journal of Neuroscience 30 August 2006, 26 (35) 9047-9056; DOI: 10.1523/JNEUROSCI.2797-06.2006
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Responses to this article

Respond to this article

Jump to comment:

  • This could be due to a reduced DHEA to cortisol ratio...
    James M. Howard
    Published on: 21 June 2007
  • Published on: (21 June 2007)
    Page navigation anchor for This could be due to a reduced DHEA to cortisol ratio...
    This could be due to a reduced DHEA to cortisol ratio...
    • James M. Howard, Biologist, independent

    In 1985, I first suggested that Alzheimer's disease may be due to low DHEA (1). In the same place, I suggested that cortisol evolved to counteract the effects of DHEA and that this is the basis of the "fight or flight" mechanism. This may explain why prolonged exposure to cortisol is so harmful because this means that DHEA is not exerting sufficient effects to counteract the negative effects of cortisol. DHEA naturally b...

    Show More

    In 1985, I first suggested that Alzheimer's disease may be due to low DHEA (1). In the same place, I suggested that cortisol evolved to counteract the effects of DHEA and that this is the basis of the "fight or flight" mechanism. This may explain why prolonged exposure to cortisol is so harmful because this means that DHEA is not exerting sufficient effects to counteract the negative effects of cortisol. DHEA naturally begins to decline around age twenty, reaching very low levels in aging while cortisol levels do not decline as dramatically. This may explain the findings of Green, et al.

    1."A Theory of the Control of the Ontogeny and Phylogeny of Homo sapiens bythe Interaction of Dehydroepiandrosterone and the Amygdala," Copyright 1985, James Michael Howard, Fayetteville, Arkansas, Registration No. TXu 220 580

    Show Less
    Competing Interests: None declared.

Related Articles

Cited By...

More in this TOC Section

Articles

  • Choice Behavior Guided by Learned, But Not Innate, Taste Aversion Recruits the Orbitofrontal Cortex
  • Maturation of Spontaneous Firing Properties after Hearing Onset in Rat Auditory Nerve Fibers: Spontaneous Rates, Refractoriness, and Interfiber Correlations
  • Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration
Show more Articles

Neurobiology of Disease

  • The stria vascularis in mice and humans is an early site of age-related cochlear degeneration, macrophage dysfunction, and inflammation
  • Restoration of sleep and circadian behavior by autophagy modulation in Huntington’s disease
  • A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament Disorganization
Show more Neurobiology of Disease
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
(JNeurosci logo)
(SfN logo)

Copyright © 2023 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.